Ovarian Tumors of Low Malignant Potential
Ovarian Tumors of Low Malignant Potential
The article by Trimble and
Trimble nicely summarizes the
state of knowledge on ovarian
tumors of low malignant potential
(LMP) and underscores the fact that
gaps in that knowledge have led to
confusion and controversy regarding
several issues related to these interesting
neoplasms. Many of these controversies
can be characterized as debates
between the "lumpers" and the "splitters."
The Johns Hopkins group has
long been at the forefront of research
on ovarian LMP tumors. In this review,
I will attempt to place some of the
authors'comments into perspective
and, at times, present a different point
and Molecular Biology
Since the original description of "semimalignant tumors" by Taylor in 1929, no consensus has been reached about the nomenclature for ovarian LMP tumors. Although we have generally used the term "borderline" in numerous publications, it has been used simply because it is less cumbersome than "tumor of low malignant potential." However, I actually prefer the latter. I totally agree with the Trimbles that the term "borderline" sends the wrong message-that the tumor is intermediate between benign and malignant. Most of the molecular biology studies of these tumors strongly suggest that they are quite distinct from frankly malignant ovarian cancers and have a very different pathogenesis. On the other hand, I strongly disagree with the use of the term "atypical proliferating tumors," which has been advanced by the Johns Hopkins group to imply that these tumors almost always behave in a benign fashion. This paradigm fundamentally fits the biology associated with stage I LMP tumors but breaks down when one considers stage II-IV tumors. The Trimbles suggest that peritoneal implants associated with ovarian LMP tumors, particularly invasive peritoneal implants, are, in fact, primary peritoneal cancers and not somehow related to the primary ovarian tumor. However, this statement is speculative and not clearly supported by molecular and genetic data. I do agree, however, that the ultimate answer to these types of theories will emerge from further molecular and clonal investigations The Trimbles also briefly discuss the introduction of the term "micropapillary," which designates a proliferative histopathologic pattern distinct from the typical serous borderline pattern. The Johns Hopkins group has proposed that so-called micropapillary serous carcinomas be split from tumors with the typical serous borderline pattern, but, as mentioned in their article, this "splitting" has not been universally accepted by either the gynecologic pathology community or the gynecologic oncology community. In fact, most prominent gynecologic pathology groups have advocated maintaining the micropapillary pattern as a subset of serous LMP tumors based on their clinicopathologic findings.[3-5] Surgical Management Issues
Because of the imprecise clinical findings associated with ovarian LMP tumors, general obstetrician/gynecologists (rather than gynecologic oncologists) are more likely to encounter these neoplasms while operating for an adnexal mass. Approximately 50% of serous tumors and 80% to 90% of mucinous LMP tumors are confined to one ovary at diagnosis. Therefore, in a high proportion of these patients who have not completed childbearing, fertility- sparing surgery-ovarian cystectomy, unilateral salpingo-oophorectomy, or some combination thereof- is feasible and highly desirable. After resection of the ovarian tumor(s), a frozen-section examination is recommended, whenever possible. Most expert gynecologic pathologists should be able to diagnose serous ovarian LMP tumors, but mucinous tumors are more problematic. I agree with the Trimbles that many pathologists may be able to state only that the tumor is "at least LMP." The diagnosis of either an ovarian LMP tumor or a frankly malignant tumor on frozen section has implications for comprehensive surgical staging. The issue of surgical staging is also controversial, even among expert gynecologic oncologists. Because these tumors, particularly those that are stage I, are associated with an excellent prognosis, and because no evidence suggests that postoperative treatment is warranted, some advocate that surgical staging is unnecessary. However, I would submit that comprehensive surgical staging is indicated when an ovarian LMP tumor is diagnosed, for the following reasons: (1) The information gained will further elucidate the biologic behavior of these tumors; (2) precise staging information will allow patients and their families to better understand their prognosis, because the risk of recurrence and death is higher in patients with extraovarian spread; (3) in some cases in which frozen-section examination suggests the diagnosis of an ovarian LMP tumor, the final diagnosis will indicate invasive ovarian cancer. In addition, once effective therapy for advanced-stage ovarian LMP tumors has been developed, there will be even more compelling reasons to justify comprehensive surgical staging. Postoperative Therapy, Prognosis, and Use of Biomarkers
The Trimbles are correct-no postoperative therapy has been shown to be effective in reducing the relapse rate or improving survival in women with advanced- stage disease. However, essentially all of these studies are retrospective, and many suffer from small numbers. Approximately 30% of women with serous tumors have disease spread beyond the ovary in the form of peritoneal implants. In reported studies, approximately 18% of patients with noninvasive peritoneal implants relapse, and approximately 6% have died of tumor.[ 2,6-14] Among patients with invasive peritoneal implants, approximately 36% relapse, and 25% have died of tumor.[2,6-12,14,15] Zanetta and colleagues have suggested that the prognosis of patients with advanced-stage tumors may be better than previously reported. However, longer follow-up may be necessary to demonstrate relapse rates reflected in the prior studies, particularly the M. D. Anderson series.[13,15] The studies from M. D. Anderson indicate that, of all patients who relapse, approximately 75% have low-grade serous carcinomas, and 25% have recurrent LMP tumors. Several clinical or clinicopathologic factors appear to be prognostic. These include FIGO stage, age at diagnosis, and residual disease at completion of primary surgery. Although several biomarkers-DNA ploidy, p53 overexpression, K-ras, and so forth-have been studied in an effort to identify patients at high risk of relapse, none have been validated in prospective trials. The Trimbles' contention that socalled recurrent LMP tumors represent either a primary peritoneal cancer missed at initial diagnosis or a new ovarian or primary peritoneal cancer is, once again, speculative. They may be correct, but the data are thus far inconclusive. The molecular biology of this phenomenon has not yet been resolved. Although studies of ovarian LMP tumors and their peritoneal implants suggest multifocality or polyclonality rather than monoclonality, the numbers of patients in these studies were small and the techniques used were few.[17,18] In addition, mutational analysis of advancedstage serous LMP tumors that subsequently "recurred" suggested a second primary tumor rather than a true recurrence. Further study is clearly indicated. Future Directions
Future research that will allow us to bridge the gaps in our knowledge of ovarian LMP tumors should focus on the following: (1) causative factors in the pathogenesis of these tumors; (2) the value of comprehensive surgical staging; (3) elucidation of clinical, pathologic, and molecular predictive and prognostic factors to select patients who are at high risk of relapse and who may benefit from postoperative therapy; (4) a search for more effective systemic therapies for advanced- stage tumors and for subsequent low-grade serous carcinomas; (5) the role of microinvasion and micropapillary pattern in prognosis and in determining optimal treatment; and (6) the clonality of the primary ovarian tumors, their peritoneal implants, and subsequent low-grade carcinomas. Such information will begin to blur the differences between the "splitters" and the "lumpers."
2. Seidman JD, Kurman RJ: Subclassification of serous borderline tumors of the ovary into benign and malignant types: A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 20:1331-1345, 1996.
3. Eichhorn JH, Bell DA, Young RH, et al: Ovarian serous borderline tumors with micropapillary and cribiform patterns: A study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 23:397- 409, 1999.
4. Deavers MT, Tortolero-Luna G, Malpica A, et al: Micropapillary and cribiform patterns and microinvasion in ovarian serous borderline tumors (SBT): A study of 99 advanced stage cases. Society of Gynecologic Oncology (abstract). Gynecol Oncol 26:280, 2000.
5. Kempson RL, Hendrickson MR: Ovarian serous borderline tumors: The citadel defended. Hum Pathol 31:525-526, 2000.
6. Kliman L, Rome RM, Fortune DW: Low malignant potential tumors of the ovary: A study of 76 cases. Obstet Gynecol 68:338-344, 1986.
7. Manchul LA, Simm J, Levin W, et al: Borderline epithelial ovarian tumors: A review of 81 cases with an assessment of the impact of treatment. Int J Radiat Oncol Biol Phys 22:867-874, 1992.
8. Russell P: Borderline epithelial tumours of the ovary: A conceptual dilemma. Clin Obstet Gynaecol 11:259-277, 1984.
9. Michael H, Roth LM: Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer 57:1240- 1247, 1986.
10. McCaughey WT, Kirk ME, Lester W, et al: Peritoneal epithelial lesions associated with proliferative serous tumours of ovary. Histopathology 8:195-208, 1984.
11. Bell DA, Weinstock MA, Scully RE: Peritoneal implants of ovarian serous borderline tumors: Histologic features and prognosis. Cancer 62:2212-2222, 1988.
12. de Nictolis M, Montironi R, Tommasoni S, et al: Serous borderline tumors of the ovary: A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer 70:152-160, 1992.
13. Gershenson DM, Silva EG, Tortolero- Luna G, et al: Ovarian serous borderline tumors with noninvasive peritoneal implants. Cancer 83:2157-2163, 1998.
14. Zanetta G, Rota S, Chiari S, et al: Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study. J Clin Oncol 19:2658-2664, 2001.
15. Gershenson DM, Silva EG, Levy L, et al: Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 82:1096- 1103, 1998.
16. Crispens MA, Bodurka D, Deavers M, et al: Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99:3-10, 2002.
17. Lu KH, Bell DA, Welch WR, et al: Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58:2328-2330, 1998.
18. Gu J, Roth LM, Younger C, et al: Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 93:1147-1152, 2001.
19. Ortiz BH, Ailawadi M, Colitti C, et al: Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res 61:7264-7267, 2001.